Biotech a healthy market for chips
15 August, 2003 by Jeremy TorrIntel is looking hard at the emerging market of biotech devices.
Former BioComm VP moves to Select
08 August, 2003 by Melissa TrudingerDr Anthony Filippis, formerly of BioComm, has joined recently listed Select Vaccines as VP of business development.
Former Coles CEO joins Starpharma board
08 August, 2003 by Melissa TrudingerStarpharma has appointed prominent Melbourne businessman Peter Bartels as a director and chairman of its board of directors, replacing Richard Oliver, who has retired.
Expat to lead UK firms to AusBiotech conference
07 August, 2003 by Melissa TrudingerDelegates from 10 UK biotechnology companies will attend the upcoming AusBiotech 2003 conference in Adelaide, led by expatriate Australian Dr John Sime, currently the director of research support and development at Imperial College, London.
Sirtex records massive result, but Gray warns of slowdown
06 August, 2003 by Melissa TrudingerSirtex Medical has reported an increase in revenues of 1368 per cent, recording more than AUD$10 million in revenues for the 12 months ending June 30, and an after-tax profit of $3.15 million.
Iatia's cash flow prompts ASX query
05 August, 2003 by Melissa TrudingerMicroscopy company Iatia has received a 'please explain' from the Australian Stock Exchange after its fourth quarter results showed the company had a net negative operating cash flow for the quarter of AUD$671,000 and $296,000 cash remaining.
CSIRO adds commerce to board
04 August, 2003 by Jeremy TorrCSIRO has beefed up its board with two new non-executive members, one of whom -- Brian Keane -- is a former CEO of insurance giant AAMI. The other is Prof Alan Robson, vice-chancellor elect of the University of Western Australia.
NSW research review team named
01 August, 2003 by Jeremy TorrThe NSW government has named a team responsible for reviewing the state's overall medical and health research program.
Sydney Uni first in Aust to license GTG patents
29 July, 2003 by Melissa TrudingerThe University of Sydney has become the first research institution in Australia to be granted a non-exclusive research licence by Genetic Technologies (GTG) to use its controversial non-coding DNA patents.
Private-public R&D interaction 'hit and miss': report
29 July, 2003 by Jeremy TorrIf Australia is to keep up with the rest of the world, it will have to make more of its public research institutes. According to a report jointly compiled by Ernst & Young and RMIT University, Australia's R&D performance needs boosting -- and the best way is to increase cooperation between public and private bodies.
Ethics committees must be more professional: Hall
23 July, 2003 by Pete YoungEthics committees helping to oversee bio-research need to be put on a more professional footing, according a leading member of Australia’s ethics community, Prof Wayne Hall.
Red letter day for synchrotron project
23 July, 2003 by Melissa TrudingerCalling today a "red letter day" for the Australian National Synchrotron project, Victorian Minister for Innovation, John Brumby, announced that Australian construction company Thiess was the successful tenderer to design and construct the building to house the 67 metre diameter machine, 30 plus beamlines, and associated laboratories, offices and technical facilities.
Monash boosted by Agilent equipment grant
18 July, 2003 by Melissa TrudingerMonash biomedical science students will get hands-on experience with mass spectrometry thanks to a US$150,000 equipment grant from Agilent Technologies awarded to the School of Biomedical Sciences today.
Biomedoz to close
16 July, 2003 by Jeremy TorrOnline industry and share market watcher Biomedoz has called it a day. Last week, the site posted a note informing users that it would close "in the next couple of days".
Macquarie launches 'virtual' biotech institute
16 July, 2003 by Jeremy TorrMacquarie University has linked together several of its existing departments, along with outside interests to build its own 'virtual' biotech research institute.
